Results 11 to 20 of about 6,081 (225)
Impact of Pre-Heart Transplant Levosimendan Administration on Post-Transplant Vasoplegia and Primary Graft Dysfunction. [PDF]
Clin TransplantABSTRACT Introduction Levosimendan, a calcium‐sensitizing inotropic agent, is used in patients with advanced heart failure (HF) awaiting heart transplantation (HT). Its prolonged effects, due to an active metabolite, may influence post‐transplant vasodilation, particularly when administered shortly before HT.
Guzman-Bofarull J +9 more
europepmc +2 more sources
New England Journal of Medicine, 2017 Commentum to "Levosimendan for the Prevention of Acute Organ Dysfunction in Sepsis"
Putzu A, Belletti A, ZANGRILLO, ALBERTO
openaire +12 more sources
Journal of Pediatric Intensive Care, 2015 We designed this review to examine the mechanism of action of levosimendan (Simdax®, Orion Pharma, Espoo, Finland) and its current clinical application in critically ill adults and children with acutely decompensated severe congestive heart failure and who require inotropic support.
Asher, Levin, Gideon, Paret
openaire +2 more sources
Levosimendan: Right for the right ventricle?* [PDF]
Critical Care Medicine, 2007 Bernard Lambermont +3 more
openalex +4 more sources
Levosimendan for amyotrophic lateral sclerosis [PDF]
The Lancet Neurology, 2021 Levosimendan is a drug developed and approved in the EU to treat severe heart failure by intravenous administration. Its principal pharmacological effect is to increase cardiac contractility by calcium sensitisation of troponin C. Because of the positive action of the drug on the neuromechanical efficiency and contractile function of the diaphragm in ...
Carvalho, Mamede, Swash, Michael
openaire +4 more sources
Biomedicines, 2023 The calcium sensitizer levosimendan is used for the treatment of acute decompensated heart failure. A small portion (4–7%) of levosimendan is metabolized to the pharmacologically active metabolite OR-1896 via the inactive intermediate OR-1855.
Hannah Kipka +4 more
doaj +1 more source
Journal of Cardiothoracic Surgery, 2020 Background Patients with moderate-severe systolic dysfunction undergoing coronary artery bypass graft have a higher incidence of postoperative low cardiac output. Preconditioning with levosimendan may be a useful strategy to prevent this complication. In
Juan José Jiménez-Rivera +9 more
doaj +1 more source
Influence of timing of Levosimendan administration on outcomes in cardiac surgery
Frontiers in Cardiovascular Medicine, 2023 PurposeThough a subgroup analysis has shown improved survival for patients suffering severely reduced ventricular function undergoing coronary artery bypass grafting, RCTs were not able to demonstrate overall beneficial effects of perioperative ...
Fridtjof Schiefenhövel +13 more
doaj +1 more source
Frontiers in Cardiovascular Medicine, 2022 BackgroundVenoarterial extracorporeal membrane oxygenation (VA-ECMO) has been increasingly used in patients with refractory cardiogenic shock (CS) or out-of-hospital cardiac arrest.
Yu-Wen Chen +10 more
doaj +1 more source
Critical Care, 2020 Background Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) has been increasingly used over the last decade in patients with refractory cardiogenic shock.
Enrique Guilherme +5 more
doaj +1 more source